.jpg)
1. The nasal vaccine should be the first booster:
COVID Task Force Chief Dr. NK Arora stated to NDTV that the nasal vaccine, iNCOVACC, cannot be administered after the booster or precaution dose has been taken. This statement came just a few days after the nasal vaccine was made available on the CoWIN platform.
Dr. Arora is in charge of NTAGI's COVID Working Group.
2. "As part of the program, no CoWIN will not accept a fourth dose" Dr. Arora responds, "as part of the program, no CoWIN will not accept a fourth dose," to the question of whether a person can take the nasal vaccine after three doses.
"Suppose you want to take a fourth dose. The term "antigen sink" is used to describe a concept. The body stops responding or responds poorly when a particular type of antigen is given to a person repeatedly. Consequently, mRNA vaccines are initially administered after a gap of six months. Later, there is a gap of three months. However, in that instance, it has been of little use. Therefore, taking a fourth dose at this time has no benefit," Dr. Arora told the media.
3. How is a nasal vaccine administered?
The nasal vaccine can be taken by mouth or through the nose. It should benefit the mucosal lining. As a result, the vaccine for the nose and mouth elicits an immune response at the virus's entry points.
It can forestall disease in that general area itself and can likewise chop down the possibilities of spread of the infection.
Sterilizing immunity is the name given to it.
A strong immune response has been observed in numerous studies when vaccines are administered through the nose.
4. In India, which nasal vaccine is available?
The novel intranasal adenovirus vaccine iNCOVACC has been approved at this time. Bharat Biotech is the manufacturer of the vaccine.
"A single dose of ChAd-SARS-CoV-2-S, administered to mice, hamsters, and macaques, provided superior protection against SARS-CoV-2 challenge. According to Bharat Biotech's official statement, "viral clearance was observed in both lower and upper airways in all these animal models after challenge with SARS-CoV-2."
5. What is the nasal vaccine's composition?
This recombinant ChAd36-SARS-CoV-S COVID-19 nasal vaccine contains NLT 5X10 particles per mL and excipients such as Tris (pH 7.4), Sodium Chloride, Magnesium Chloride, Glycerol, and Polysorbate-80.
6. Are they superior to vaccines that can be injected?
There is evidence that nasal vaccines are superior to injectable vaccines. With two doses administered four weeks apart in the third phase of the clinical trial, which involved 3,000 participants, iNCOVACC demonstrated good immunity.
The respiratory system is protected by the intramucosal vaccine. Benjamin Goldman-Israelow, a physician-scientist at Yale School of Medicine in New Haven, Connecticut, told Nature that these localized cells "act as sentinels at the site of infection." They are able to act much more rapidly.
7.What nasal vaccines are available outside of India?
China has approved a vaccine that does not require a needle. CanSino Biologics in Tianjin developed China's nasal vaccine. In China, it is used as a booster dose.
The nasal vaccine is approved in India as a two-dose primary vaccine rather than as a booster.